Ulixacaltamide's Titration Patent Allowance Bolsters IP, Reaffirming Value Proposition

Research evidence excerpt

Ulixacaltamide's Titration Patent Allowance Bolsters IP, Reaffirming Value Proposition

-TYPE CALCIUM CHANNEL MODULATORS". As a summary, recall that Research Analyst, Piper Sandler & Co.

this patent covers claims regarding ulixacaltamide's titration scheme. For instance, 646 656-5259, liam.hiester@psc.com

ulixacaltamide is administered starting at a daily dose of 5-40 mg for the initial period Dominic Lorenzi

of time, followed by up-titration to increase to the maximum dose of 20-120 mg/day. Research Analyst, Piper Sandler & Co.

That said, on December 4, 2025, The Office Action rejected Claims 1-3, 5-6, 9, 12-16, 646 951-0692, dominic.lorenzi@psc.com

18-19 and 21-31 of this patent application under 35 U.S.C. § 112, first paragraph (due

to allegedly failing to comply with the enablement requirement). Consequently, PRAX RISKS TO ACHIEVEMENT OF

PT & RECOMMENDATION filed an Amendment and Response to Non-Final Office Action on May 4, 2026, in which:

Clinical and regulatory risks for ulixacaltamide, "claims 1-3, 5-6, 9 and 23-25 have been canceled without prejudice; claims 12, 14-16,

relutrigine, vormatrigine, elsunersen

18-19, 21-22, 26-27 and 30 have been amended; and new claims 32-46 have been

added". Impressively, we were pleased to see that in just a few weeks, the Examiner Price Performance - 1 Year

at the USPTO provided a Notice of Allowance, which ultimately deems this patent as USD

allowable under the contents included in the application/response. 400

• We believe this patent further strengthens ulixacaltamide's robust IP portfolio 300

and helps to bolster potential IP out to ~2042 (not including PTE). Overall, the 250

received allowance of patent application 17/975,457 marks a crucial step towards 200

bolstering ulixacaltamide's IP portfolio.